Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis
- PMID: 18802361
- DOI: 10.1159/000155747
Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis
Abstract
Background and objectives: Allergy to house dust mite is one of the most common causes of allergic rhinitis (AR) in China. We sought to compare the efficacy and safety of a 6-week cluster schedule of specific immunotherapy with that of a 14-week conventional schedule for the treatment of subjects with persistent AR.
Methods: The trial was a prospective and randomized study involving 96 patients with persistent AR, aged 14-60 years, who were allergic to Dermatophagoides pteronyssinus. While 48 patients were randomly assigned to the cluster schedule reaching the maintenance dose within 6 weeks, the other 48 were randomly assigned to the conventional schedule reaching the maintenance dose within 14 weeks. Eighty-nine patients completed a 1-year treatment course. While kinetic changes in clinical efficacy and adverse reactions were observed during the treatment, quality of life, cutaneous reactivity and serum-specific immunoglobulin E to Dermatophagoides pteronyssinus were measured before and after treatment.
Results: The cluster schedule reduced the time to reach the maintenance dose by 57% and caused mild systemic adverse reactions after 1.0% of injections (6.7% of patients), with no differences in comparison with the conventional schedule. Cluster specific immunotherapy led to decreases in clinical symptoms and earlier use of medication than did the conventional schedule. Similar improvements in quality of life and reduced cutaneous reactivity without significant changes in specific immunoglobulin E were observed in both groups after 1 year.
Conclusions: The cluster schedule is a safe alternative to the conventional schedule with the advantage of achieving clinical effectiveness sooner.
Copyright 2008 S. Karger AG, Basel.
Similar articles
-
Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus.J Allergy Clin Immunol. 2005 Jul;116(1):109-18. doi: 10.1016/j.jaci.2005.05.005. J Allergy Clin Immunol. 2005. PMID: 15990782 Clinical Trial.
-
[Comparative study on cluster and conventional immunotherapy with Dermatophagoides pteronyssinus in patients with allergic rhinitis].Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Dec;46(12):981-5. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011. PMID: 22336008 Clinical Trial. Chinese.
-
Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial.Laryngoscope. 2013 Jun;123(6):1334-40. doi: 10.1002/lary.23935. Epub 2013 Apr 24. Laryngoscope. 2013. PMID: 23616386 Clinical Trial.
-
Immunotherapy in allergic rhinitis.Allerg Immunol (Paris). 2001 Oct;33(8):323-6. Allerg Immunol (Paris). 2001. PMID: 11763723 Review.
-
Accelerated immunotherapy schedules: review of efficacy and safety.Ann Allergy Asthma Immunol. 2006 Aug;97(2):126-37; quiz 137-40, 202. doi: 10.1016/S1081-1206(10)60003-8. Ann Allergy Asthma Immunol. 2006. PMID: 16937741 Review.
Cited by
-
[Safety comparison of omalizumab and glucocorticoid in rush allergen immunotherapy].Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020 Jul;34(7):610-614. doi: 10.13201/j.issn.2096-7993.2020.07.008. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020. PMID: 32791635 Free PMC article. Chinese.
-
Qingfeijianpi therapy for persistent allergic rhinitis: A randomized, positive-controlled clinical trial.Medicine (Baltimore). 2018 Jun;97(23):e10961. doi: 10.1097/MD.0000000000010961. Medicine (Baltimore). 2018. PMID: 29879045 Free PMC article. Clinical Trial.
-
Cloning, bioinformatics analysis, and expression of the dust mite allergen Der f 5 of Dermatophagoides farinae.Braz J Med Biol Res. 2012 Aug;45(8):746-52. doi: 10.1590/s0100-879x2012007500077. Epub 2012 May 17. Braz J Med Biol Res. 2012. PMID: 22584646 Free PMC article.
-
A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacy.Immun Inflamm Dis. 2014 Aug;2(2):92-8. doi: 10.1002/iid3.23. Epub 2014 May 29. Immun Inflamm Dis. 2014. PMID: 25400929 Free PMC article.
-
A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol.Allergy. 2014 Dec;69(12):1629-38. doi: 10.1111/all.12513. Epub 2014 Oct 6. Allergy. 2014. PMID: 25130503 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials